Kadmon Presents Preclinical Data Supporting the Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis

March 28, 2017

Kadmon Presents Preclinical Data Supporting the Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis

-- Data Validate the Role of ROCK Signaling in Fibrotic Disease --

NEW YORK--(BUSINESS WIRE)-- Kadmon Holdings, Inc. (NYSE:KDMN) (“Kadmon”) today announced preclinical data demonstrating the importance of the Rho-associated coiled-coil kinase (ROCK) signaling pathway in the pathogenesis of pulmonary fibrosis, supporting the therapeutic potential of ROCK inhibition to treat the disease. The data will be presented today as a poster at the 2017 Keystone Symposia on Injury, Inflammation and Fibrosis, taking place in Snowbird, UT.

“These data demonstrate that ROCK inhibition blocks multiple cell signaling mechanisms that drive pulmonary fibrosis, including α-SMA expression and endothelial and epithelial cell function,” said Masha Poyurovsky, PhD, Vice President, Head of Molecular Signaling at Kadmon. “By targeting ROCK, we can disrupt fundamental aspects of the TGFβ signaling pathway to potentially treat pulmonary fibrosis.”

Recent studies conducted by Kadmon and others have shown that ROCK signaling plays a key role in the development of pulmonary fibrosis, or scarring of the lungs that can lead to organ failure and death. Specifically, the ROCK pathway mediates cell signaling of Transforming Growth Factor-β (TGFβ), a master regulator of wound healing response that is essential for proper functions of multiple tissues. By targeting ROCK, Kadmon researchers believe that they can inhibit fibrosis while avoiding the toxicities associated with broad TGFβ inhibition.

To investigate the therapeutic potential of ROCK inhibition in fibrosis, Kadmon researchers generated a series of potent small molecule ROCK inhibitors and assessed their ability to modulate cellular mechanisms underlying aberrant signaling in pulmonary fibrosis. The findings demonstrated that ROCK inhibition blocks the expression of α-smooth muscle actin (α-SMA), the defining component of fibrosis-causing myofibroblast cells. Along with targeting α-SMA expression, ROCK inhibition reduces the activity of endothelial cells and epithelial cells, major contributors to the progressive organ injury associated with fibrosis. In summary, researchers determined that ROCK activity is essential to the fibrotic process and that ROCK inhibition shows potential in treating pulmonary fibrosis.

“Through our ROCK research platform, we continue to establish the importance of ROCK signaling in fibrotic disease,” said Harlan W. Waksal, M.D., President and CEO at Kadmon. “These findings further support the clinical development of our ROCK inhibitor KD025, for which we have three ongoing Phase 2 clinical trials, including in idiopathic pulmonary fibrosis.”

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company developing innovative products for significant unmet medical needs. We have a diversified product pipeline in autoimmune and fibrotic diseases, oncology and genetic diseases.

Forward-Looking Statements

This press release contains forward-looking statements. Such statements may be preceded by the words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. In particular, forward-looking statements include statements regarding the expected proceeds from and timing of the closing of the private placement, the use of proceeds from the private placement and the anticipated filing of a registration statement to cover resales of common stock issuable in connection with the private placement. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) our reliance on the success of our product candidates; (iv) the timing or likelihood of regulatory filings and approvals; (v) our ability to expand our sales and marketing capabilities; (vi) the commercialization of our product candidates, if approved; (vii) the pricing and reimbursement of our product candidates, if approved; (viii) the implementation of our business model, strategic plans for our business, product candidates and technology; (ix) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (x) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xi) costs associated with defending intellectual property infringement, product liability and other claims; (xii) regulatory developments in the United States, Europe and other jurisdictions; (xiii) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xiv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xv) our ability to maintain and establish collaborations or obtain additional grant funding; (xvi) the rate and degree of market acceptance of our product candidates; (xvii) developments relating to our competitors and our industry, including competing therapies; (xviii) our ability to effectively manage our anticipated growth; (xix) our ability to attract and retain qualified employees and key personnel; (xx) our ability to close this transaction; and (xxi) our ability to achieve cost savings and other benefits from our efforts to streamline our operations and to not harm our business with such efforts. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in the Kadmon’s filings with the SEC, including Kadmon’s Annual Report on Form 10-K filed pursuant to Section 13 of the Securities Exchange Act of 1934, as amended, with the SEC on March 22, 2017. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. Kadmon assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

For Kadmon Holdings, Inc.
Investor Relations
Ellen Tremaine, 646-490-2989
ellen.tremaine@kadmon.com
or
Maeve Conneighton, 212-600-1902
maeve@argotpartners.com

Source: Kadmon Holdings, Inc.